Pharmaceuticals & Biotechnology | Pharma & Biotech Resources

Elia Stupka, Scientific Director of Bioinformatics at UCL Genomics, joins Helen Winsor form Pharma IQ, to discuss next-generation DNA sequencing and recent developments in next-generation sequencing technologies. Stupka also shares his insights on building novel systems biology

  Peter Kjaer, Head of Patents at Lego, joins Helen Winsor from Pharma IQ, to discuss intellectual property right trends in the Nordic region. With patent trolls still a key concern, Kjaer explains why these provide an ongoing threat and why companies are struggling to come up with

Karol Sikora Medical Director at CancerPartners UK, joins Helen Winsor from Pharma IQ, to discuss new trial design approaches and biomarker application methods coming on stream to drive oncology clinical development. The main focus of this exclusive interview is on assessing molecular

New techniques for developing drug delivery mechanisms have led to two new particle engineering approaches that offer unique formula opportunities. Dr. Cory Berkland, Associate Professor at the University of Kansas, joins Amber Scorah from Pharma IQ, to talk about nanocluster

Yann Kervevan, EMEA Regulatory Affairs Operations Manager, Alexion Pharmaceuticals, joins Helen Winsor from Pharma IQ, to dicsuss the challenges in eCTD implementation and electronic submissions. Firstly Kervevan offers some best practice tips for industry on converting and assembling

As part of the new Pharma Leaders Today series, Allen E. Norris, Vice President and Head Group IP at UCB Pharma, speaks to Andrea Charles from Pharma IQ, about current trends in biopatents and how pharma companies can readdress the imbalance between new product

Dr. Rajendra Jani, Senior Vice President and Head of Clinical R&D, Cadila Healthcare , joins Andrea Charles from Pharma IQ, to discuss how to increase the efficiency of your clinical trials whilst retaining quality and current trends for clinical trials in India. In the second half

Dr. Walter Stewart, Associate Chief Research Officer at  Geisinger Center for Health Research, joins Andrea Charles from Pharma IQ, to discuss how biobanking can be leveraged to improve healthcare delivery. Stewart also shares his insights on the challenges of running a large-scale

Prof. Dr. Ahmed Elzawawy, President of  International Campaign for Establishment and Development of Oncology Centres (ICEDOC) & Co-President of South and East Mediterranean   College of Oncology ( SEMCO), speaks to Andrea Charles from Pharma IQ, about the challenges

Stephen Brown, CTO of Vivalis and a Member of the Single Use Task Force, PDA, joins Helen Winsor from Pharma IQ, to discuss the application of risk management strategies when implementing single-use systems (SUS). First Brown outlines how best to implement a full SUS and the vital

Dr. Frank Floether, Ex Vice-President Business Development Asia Pacific for Johnson and Johnson, speaks to Andrea Charles from Pharma IQ, about the  common mistakes pharmaceutical companies make when entering emerging markets and his top 3 tips for developing a robust Asia

Pharmacovigilance is an important and integral part of clinical research . Elie Magdalani, Regional Manager, Medical and Pharmacovigilance Affairs Egypt and North Africa, Ranbaxy Egypt, joins Andrea Charles from Pharma IQ, to talk about how we can ensure the proactive and

In this exclusive interview Sean Fenske, Editor-in-Chief for Medical Design Technology (MDT), speaks to Chris Archer from Pharma IQ, about the rapid adoption of medical electronic devices in an ever changing environment and overcoming the challenges of medical

As part of the new Pharma Leaders Today series, Peter Pitts, President and co-founder of the Center for Medicine in the Public Interest and Partner/Director Global Healthcare, Porter Novelli, spoke to Andrea Charles from Pharma IQ, about the personalised medicine and the

Dr. Wolfgang Eglmeier, Head of Clinical Operations Germany, Grünenthal GmbH, joins Helen Winsor from Pharma IQ, to discuss optimising clinical development in CNS. He outlines the main challenges when recruiting for CNS trials and some strategies that can be employed to aid